CytoMed Therapeutics Limited Ordinary Shares (NASDAQ:GDTC) — Stock Price
CytoMed Therapeutics Limited Ordinary Shares (NASDAQ:GDTC) is currently trading at $0.80 USD, down 2.55% today. Over the past 52 weeks, shares have ranged between $0.72 and $2.69. This page tracks CytoMed Therapeutics Limited Ordinary Shares's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see GDTC company net worth.
CytoMed Therapeutics Limited Ordinary Shares (GDTC) Stock Price Chart — Daily History & Trading Volume
The chart below tracks CytoMed Therapeutics Limited Ordinary Shares's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
CytoMed Therapeutics Limited Ordinary Shares Income Statement — Revenue, Profit & Earnings by Year
CytoMed Therapeutics Limited Ordinary Shares's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $319.20K | $69.50K | $509.12K | $365.60K | $84.18K |
| Cost of Revenue | $1.21 Million | $17.12K | $3.74K | $109.04K | $3.50K |
| Gross Profit | $-886.56K | $52.38K | $505.39K | $-109.04K | $110.29K |
| Research & Development | $2.18 Million | $1.95 Million | $1.59 Million | $1.52 Million | $1.09 Million |
| SG&A | $1.84 Million | $1.70 Million | $455.54K | $596.51K | $585.98K |
| Total Operating Expenses | $3.63 Million | $3.18 Million | $2.08 Million | $2.17 Million | $1.27 Million |
| Operating Income | $-4.52 Million | $-3.13 Million | $-1.58 Million | $-2.28 Million | $-1.16 Million |
| EBITDA | $-4.30 Million | $-2.44 Million | $-3.89 Million | $-1.47 Million | $-1.42 Million |
| EBIT | $-4.52 Million | $-2.57 Million | $-3.99 Million | $-1.87 Million | $-1.75 Million |
| Interest Expense | $20.57K | $20.75K | $50.52K | $122.15K | $118.39K |
| Income Before Tax | $-3.93 Million | $-2.58 Million | $-4.14 Million | $-3.05 Million | $-2.06 Million |
| Income Tax Expense | — | — | $653.00 | $1.60K | $-53.43K |
| Net Income | $-3.92 Million | $-2.57 Million | $-4.14 Million | $-3.06 Million | $-2.07 Million |
CytoMed Therapeutics Limited Ordinary Shares Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes CytoMed Therapeutics Limited Ordinary Shares's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $7.98 Million | $10.07 Million | $12.40 Million | $5.25 Million | $6.10 Million |
| Total Current Assets | $3.66 Million | $6.00 Million | $10.12 Million | $2.51 Million | $3.29 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | $200.35K | $47.19K | $11.56K | $15.27K |
| Net Receivables | $132.05K | $18.78K | $204.75K | $54.54K | $15.22K |
| Inventory | — | $838.64K | $680.59K | $578.85K | $432.59K |
| Property, Plant & Equipment | — | — | — | $2.47 Million | $2.50 Million |
| Goodwill | $355.00 | $354.92 | $355.97 | $356.65 | $355.83 |
| Total Liabilities | $1.13 Million | $1.02 Million | $1.13 Million | $4.66 Million | $3.50 Million |
| Total Current Liabilities | $709.17K | $606.49K | $718.90K | $4.18 Million | $2.94 Million |
| Long-term Debt | $368.66K | $394.31K | $407.77K | $468.83K | $539.12K |
| Net Debt | $-1.61 Million | $-4.51 Million | $-8.57 Million | $2.65 Million | $747.67K |
| Total Stockholder Equity | $6.54 Million | $8.96 Million | $11.28 Million | $589.71K | $2.60 Million |
| Retained Earnings | $-18.83 Million | $-14.84 Million | $-12.37 Million | $-8.24 Million | $-5.08 Million |
CytoMed Therapeutics Limited Ordinary Shares Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how CytoMed Therapeutics Limited Ordinary Shares generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-3.70 Million | $-2.71 Million | $-3.54 Million | $-1.40 Million | $-1.72 Million |
| Capital Expenditures | $703.13K | $1.40 Million | $58.45K | $476.00K | $583.71K |
| Free Cash Flow | $-4.40 Million | $-4.11 Million | $-3.60 Million | $-1.88 Million | $-2.30 Million |
| Investing Cash Flow | $929.28K | $675.32K | $-2.79 Million | $-475.51K | $-825.59K |
| Financing Cash Flow | $208.65K | $-45.55K | $10.80 Million | $968.72K | $4.18 Million |
| Dividends Paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Stock-Based Compensation | $694.20K | $0.00 | $0.00 | — | — |
| Depreciation | $401.58K | $335.29K | $382.19K | $394.69K | $330.65K |
| Change in Cash | $-2.60 Million | $-1.74 Million | $4.68 Million | $-920.04K | $1.61 Million |
CytoMed Therapeutics Limited Ordinary Shares Earnings History — EPS Actual vs. Analyst Estimates
Track CytoMed Therapeutics Limited Ordinary Shares's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 30, 2026 | 0.00 | -0.04 | +100.00% |
| Oct 02, 2025 | -0.19 | -0.04 | -375.00% |
| Sep 30, 2025 | — | — | — |
| Apr 28, 2025 | -0.12 | -0.04 | -200.00% |
| Dec 31, 2024 | — | -0.04 | — |
| Nov 27, 2024 | -0.04 | -0.04 | +0.00% |
| Sep 30, 2024 | -0.09 | -0.04 | -125.00% |
| May 29, 2024 | -0.04 | -0.04 | +0.00% |